Ignite Proteomics Announces Prospective 10,000-Patient Oncology Registry to Evaluate Functional Proteomics in Cancer Therapy Selection

Key Takeaways

• Ignite launches 10,000‑patient registry linking RPPA data to outcomes.
• Registry targets ADC and immunotherapy in breast, lung, GI cancers.
• Projected $13 million revenue over agreement lifespan for Ignite.
• RPPA platform quantifies 32+ proteins from routine FFPE tissue.
• Dataset may fuel AI diagnostics, payer evidence, and companion tests.

Pulse Analysis

Functional proteomics has emerged as a missing link in precision oncology, offering a dynamic view of tumor biology that genomic tests cannot capture. Ignite’s Reverse Phase Protein Array (RPPA) technology quantifies over 30 proteins and phosphoproteins from standard FFPE samples, delivering actionable insights into pathway activation and drug target expression. As antibody‑drug conjugates and immunotherapies become mainstays across multiple tumor types, clinicians need robust, protein‑level biomarkers to guide therapy selection and anticipate resistance, positioning RPPA as a complementary tool to existing diagnostics.

The newly announced 10,000‑patient registry will systematically collect RPPA profiles at key treatment decision points, record the therapies chosen, and track longitudinal outcomes. Targeting breast, lung, and gastrointestinal malignancies, the program aligns with the rapid expansion of ADCs and immune‑based regimens. Ignite projects roughly $13 million in revenue from the agreement, reflecting both the commercial value of the testing service and the strategic importance of the data it will generate. Enrollment is slated to begin in fall 2026 through a network of community and academic oncology practices, ensuring broad geographic and practice‑type representation.

Beyond immediate revenue, the registry’s real‑world dataset positions Ignite to develop AI‑enabled diagnostic algorithms, support payer evidence packages, and forge companion‑diagnostic collaborations with pharmaceutical firms. By providing a structured evidence base that ties protein signaling to clinical response, the initiative could accelerate regulatory acceptance of functional proteomics and influence reimbursement policies. In a market where treatment complexity is rising, such data assets are likely to become differentiators for firms seeking to lead the next wave of precision‑oncology decision support.